Inogen (Inogen) Debt-to-Revenue

: 0.07 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Debt-to-Revenue measures a company's ability to pay off its debt.

Inogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.7 Mil. Inogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18.3 Mil. Inogen's annualized Revenue for the quarter that ended in Dec. 2023 was $303.6 Mil. Inogen's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.07.

Inogen Debt-to-Revenue Historical Data

The historical data trend for Inogen's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

0.02

0.03

0.08

0.06

0.07

Inogen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue																0.07	0.08	0.07	0.07	0.07

Competitive Comparison

For the Medical Devices subindustry, Inogen's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inogen Debt-to-Revenue Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Inogen's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Inogen's Debt-to-Revenue falls into.

Inogen Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Inogen's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.653	+	18.27)	/	315.66
	=	0.07

Inogen's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.653	+	18.27)	/	303.584
	=	0.07

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Inogen Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Inogen's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Inogen (Inogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inogen Inc (NAS:INGN) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

6IO:Germany

Address

301 Coromar Drive, Goleta, CA, USA, 93117

Website

https://www.inogen.com

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, Inogen sells its products through distributors or large gas companies and home oxygen providers. Inogen generates the majority of its revenue in the United States.

Executives

Thomas A. West	director	C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Stanislav Glezer	officer: EVP, Chief Medical Officer	C/O INOGEN, INC., 326 BOLLAY DRIVE., GOLETA CA 93117
Jason Somer	officer: EVP, Gen. Counsel & Secretary	C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Glenn S Boehnlein	director	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Mary Kay Ladone	director	130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601
Kevin M King	director	C/O AFFYMETRIX, INC., 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Kristin A. Caltrider	officer: EVP, CFO and Treasurer	C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Anderson Ray Benjamin M	director	1100 NORTH WASHINGTON STREET, DELPHI IN 46923
Michael K. Sergesketter	officer: EVP, CFO and Treasurer	301 COROMAR DRIVE, GOLETA CA 93117
Raymond Huggenberger	director, officer: See Remarks	326 BOLLAY DRIVE, GOLETA CA 93117
Alison Bauerlein	officer: See Remarks	326 BOLLAY DRIVE, GOLETA CA 93117
Brenton Taylor	officer: Vice President, Engineering	326 BOLLAY DRIVE, GOLETA CA 93117
Elizabeth Mora	director	C/O MKS INSTRUMENTS, INC., 2 TECH DRIVE, SUITE 201, ANDOVER MA 01810
George J Parr	director	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Byron Myers	officer: Vice President, Marketing	326 BOLLAY DRIVE, GOLETA CA 93117